Which has preferable valuation & earnings, MPH or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

Do analysts rate 4BB or IMM?

4basebio currently has a consensus price target of GBX 1,400, indicating a potential upside of 174.51%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts plainly believe 4basebio is more favorable than ImmuPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 ImmuPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or IMM more profitable?

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% ImmuPharma 3,519.56% -353.21% -43.00%

Which has higher valuation & earnings, FARN or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£11.52 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

Which has stronger earnings and valuation, POLB or IMM?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Poolbeg Pharma N/A N/A -£4.50B -£0.94 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

Does the media prefer POLB or IMM?

In the previous week, ImmuPharma had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 2 mentions for ImmuPharma and 1 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.00 beat ImmuPharma's score of -0.47 indicating that Poolbeg Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OBI or IMM?

In the previous week, Ondine Biomedical and Ondine Biomedical both had 2 articles in the media. Ondine Biomedical's average media sentiment score of 0.78 beat ImmuPharma's score of -0.47 indicating that Ondine Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ondine Biomedical 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

ImmuPharma (IMM) Competitors

GBX 3.20 -0.30 (-8.43%)

As of 09/15/2026 12:29 PM Eastern

Compare

IMM vs. MPH, 4BB, FARN, POLB, and OBI

Should you buy ImmuPharma stock or one of its competitors? ImmuPharma's main competitors and comparable companies include Mereo BioPharma Group plc (MPH.L) (MPH), 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), Poolbeg Pharma (POLB), and Ondine Biomedical (OBI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

In the previous week, ImmuPharma had 2 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 2 mentions for ImmuPharma and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 beat ImmuPharma's score of -0.47 indicating that Mereo BioPharma Group plc (MPH.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
ImmuPharma	Neutral

ImmuPharma has a net margin of 3,519.56% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
ImmuPharma	3,519.56%	-353.21%	-43.00%

6.1% of ImmuPharma shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ImmuPharma beats Mereo BioPharma Group plc (MPH.L) on 5 of the 9 factors compared between the two stocks.

How does ImmuPharma compare to 4basebio?

4basebio (LON:4BB) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
ImmuPharma	3,519.56%	-353.21%	-43.00%

ImmuPharma has lower revenue, but higher earnings than 4basebio. ImmuPharma is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	46.65	-£9.84M	-£109.00	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

4basebio has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, meaning that its stock price is 201% more volatile than the broader market.

4basebio currently has a consensus price target of GBX 1,400, indicating a potential upside of 174.51%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts plainly believe 4basebio is more favorable than ImmuPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ImmuPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ImmuPharma had 2 more articles in the media than 4basebio. MarketBeat recorded 2 mentions for ImmuPharma and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 beat ImmuPharma's score of -0.47 indicating that 4basebio is being referred to more favorably in the media.

Company	Overall Sentiment
4basebio	Neutral
ImmuPharma	Neutral

Summary

4basebio beats ImmuPharma on 8 of the 15 factors compared between the two stocks.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Faron Pharmaceuticals Oy has a beta of 1.116, indicating that its stock price is 12% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, indicating that its stock price is 201% more volatile than the broader market.

In the previous week, ImmuPharma had 2 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 2 mentions for ImmuPharma and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 beat ImmuPharma's score of -0.47 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
ImmuPharma	Neutral

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%
ImmuPharma	3,519.56%	-353.21%	-43.00%

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, ImmuPharma had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 2 mentions for ImmuPharma and 1 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.00 beat ImmuPharma's score of -0.47 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Poolbeg Pharma is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Poolbeg Pharma has a beta of 1.828, suggesting that its stock price is 83% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, suggesting that its stock price is 201% more volatile than the broader market.

5.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 6.2% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Poolbeg Pharma's net margin of 0.00%. Poolbeg Pharma's return on equity of -55.47% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
ImmuPharma	3,519.56%	-353.21%	-43.00%

Summary

ImmuPharma beats Poolbeg Pharma on 7 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Ondine Biomedical?

Ondine Biomedical (LON:OBI) and ImmuPharma (LON:IMM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

32.8% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ondine Biomedical has a beta of 0.308, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, suggesting that its stock price is 201% more volatile than the broader market.

In the previous week, Ondine Biomedical and Ondine Biomedical both had 2 articles in the media. Ondine Biomedical's average media sentiment score of 0.78 beat ImmuPharma's score of -0.47 indicating that Ondine Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ondine Biomedical	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ondine Biomedical has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

ImmuPharma has a net margin of 3,519.56% compared to Ondine Biomedical's net margin of -1,117.06%. ImmuPharma's return on equity of -353.21% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
ImmuPharma	3,519.56%	-353.21%	-43.00%

Summary

Ondine Biomedical beats ImmuPharma on 6 of the 11 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMM vs. The Competition

Export

Metric	ImmuPharma	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£20.00M	£3.89B	£7.21B	£2.88B
Dividend Yield	0.77%	3.65%	2.57%	6.26%
P/E Ratio	-8.66	14.11	272.84	366.92
Price / Sales	N/A	1,434.33	701.69	90,001.88
Price / Cash	20.50	108.94	77.71	27.89
Price / Book	4.97	15.17	10.37	6.33
Net Income	-£2.51M	-£22.78M	£3.49B	£5.89B
7 Day Performance	-17.82%	-0.71%	-0.76%	-0.36%
1 Month Performance	-26.99%	0.29%	-0.39%	-0.68%
1 Year Performance	-78.49%	39.41%	18.93%	19.86%

ImmuPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMM ImmuPharma	N/A	GBX 3.21 -8.4%	N/A	-81.7%	£20.00M	N/A	N/A	13	News Coverage Earnings Report
MPH Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	N/A	£89.76M	N/A	N/A	50	Gap Down
4BB 4basebio	N/A	GBX 500 +5.3%	GBX 1,400 +180.0%	-39.2%	£77.43M	£1.69M	N/A	101	Gap Up
FARN Faron Pharmaceuticals Oy	N/A	GBX 37.15 -2.2%	N/A	-82.1%	£75.37M	N/A	N/A	34
POLB Poolbeg Pharma	N/A	GBX 8.25 -3.8%	N/A	+99.0%	£62.98M	N/A	N/A	12

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IMM) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuPharma (IMM) Competitors

IMM vs. MPH, 4BB, FARN, POLB, and OBI

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Summary

How does ImmuPharma compare to 4basebio?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Summary

How does ImmuPharma compare to Poolbeg Pharma?

Summary

How does ImmuPharma compare to Ondine Biomedical?

Summary

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuPharma (IMM) Competitors

IMM vs. MPH, 4BB, FARN, POLB, and OBI

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Which has preferable valuation & earnings, MPH or IMM?

Does the media favor MPH or IMM?

Is MPH or IMM more profitable?

Do insiders & institutionals hold more shares of MPH or IMM?

Summary

How does ImmuPharma compare to 4basebio?

Is 4BB or IMM more profitable?

Which has preferable earnings & valuation, 4BB or IMM?

Which has more volatility and risk, 4BB or IMM?

Do analysts rate 4BB or IMM?

Do insiders and institutionals believe in 4BB or IMM?

Does the media prefer 4BB or IMM?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Do institutionals and insiders have more ownership in FARN or IMM?

Which has more risk & volatility, FARN or IMM?

Does the media refer more to FARN or IMM?

Is FARN or IMM more profitable?

Which has higher valuation & earnings, FARN or IMM?

Summary

How does ImmuPharma compare to Poolbeg Pharma?

Does the media prefer POLB or IMM?

Which has stronger earnings and valuation, POLB or IMM?

Which has more volatility & risk, POLB or IMM?

Do institutionals and insiders have more ownership in POLB or IMM?

Is POLB or IMM more profitable?

Summary

How does ImmuPharma compare to Ondine Biomedical?

Do institutionals & insiders believe in OBI or IMM?

Which has more volatility & risk, OBI or IMM?

Does the media favor OBI or IMM?

Which has stronger earnings and valuation, OBI or IMM?

Is OBI or IMM more profitable?

Summary

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools